Company profile

Lyell Immunopharma F

Lyell Immunopharma has raised $493 million across early seed and large-stage financing, including seed backing (2018), a Series C led by GSK (Mar 12, 2020) for expanded R&D, and a $100M Post-IPO tranche on July 25, 2025. Founded in 2018, Lyell advances engineered cell therapies CAR-T and TIL approaches ttargeting solid tumors and hematologic disease. Funding supported translational research,

Back to profiles

Quick facts

Total funding: $493 million
Founded: 2018

Notable investors

GSK (Mar 12

Reach buyers like Lyell Immunopharma F on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Lyell Immunopharma F
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Lyell Immunopharma F.

The 14-day trial ships every feature, no card required.

Start free →